References
- Rossouw JE, Anderson GL, Prentice RL, . Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
- Naftolin F, Schneider HP, Sturdee DW. Executive Committee of the International Menopause Society. Guidelines for the hormone treatment of women in the menopausal transition and beyond. Climacteric 2004;7:8–11
- Klaiber EL, Vogel W, Rako S. A critique of the Women's Health Initiative hormone therapy study. Fertil Steril 2005;84:1589–601
- Mizunuma H, Okano H, Soda M, . Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study. Maturitas 1997;27:69–76
- Yasui T, Umino T, Takikawa M, . Effects of postmenopausal hormone therapy every day and every other day on lipid levels according to difference in body mass index. Menopause 2005;12:223–31
- Crandall C. Low-dose estrogen therapy for menopausal women: A review of efficacy and safety. J Womens Health(Larchmt) 2003;12:723–47
- Ettinger B. Vasomotor symptom relief versus unwanted effects: role of estrogen dosage. Am J Med 2005;118:74–8S
- Lobo RA. The rationale for low-dose hormonal therapy. Endocrine 2004;24:217–21
- Tie-Hua NG. Choice of delta in equivalence testing. Drug Inf J 2001;35:1517–27
- Speroff L, Whitcomb RW, Kempfert NJ, Boyd RA, Paulissen JB, Rowan JP. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms. Obstet Gynecol 1996;88:587–92
- Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:1065–79
- Utian WH, Burry KA, Archer DF, . Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. The Esclim Study Group. Am J Obstet Gynecol 1999;181:71–9
- De Aloysio D, Rovati LC, Giacovelli G, Setnikar I, Bottiglioni F. Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches. A randomized, double-blind placebo-controlled study. Drug Res 2000;50:293–300
- Prior JC, Nelsen JD, Hitchcock CL, Williams LA, Vigna YM, Dean CB. Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy. Clin Sci 2007;112: 517–25
- Ettinger B, Pressman A, Gessel AV. Low-dosage esterified estrogens opposed by progestin at 6-month intervals. Obstet Gynecol 2001;98:205–11
- Fletcher CD, Farish E, Dagen MM, Hart DM. Short-term changes in lipoproteins and apoproteins during cyclical oestrogen-progestogen replacement therapy. Maturitas 1991;14:33–42
- Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Different effects of oral conjugated equine estrogen and transdermal estrogen replacement therapy on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 2002;106:1771–6
- Wakatsuki A, Ikenoue N, Shinohara K, Watanabe K, Fukaya T. Different effects of oral and transdermal estrogen replacement therapy on matrix metalloproteinase and their inhibitor in postmenopausal women. Arterioscler Thromb Vasc Biol 2003;23: 1948–9
- Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010;8:979–86
- Renoux C, Dell'Aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;340:c2519